Algen Biotechnologies

algenbio.com →

-49%

est. 2Y upside i

HealthcareSeries D+

Using CRISPR to find treatments for cancer and inflammation

Rank

#2943

Sector

Biotechnology

Est. Liquidity

~3Y

Data Quality

Data: Medium

Algen Biotechnologies presents a moderate upside opportunity for a job seeker, driven by its strong proprietary AI-driven CRISPR platform and a significant multi-target partnership with AstraZeneca.

Last updated: February 25, 2026

Bull (20%)+100%

Algen successfully progresses its internal drug pipeline, achieving key clinical milestones, and expands its multi-target partnership with AstraZeneca or secures additional major pharmaceutical collaborations. This validates the AlgenBrain platform's efficacy, driving revenue growth through upfront payments and milestones, and justifying a $700M+ valuation, a 2x increase from the current estimated $350M.

Base (50%)+40%

Algen continues to execute on its AstraZeneca partnership, meeting initial milestones, and makes steady progress on its internal discovery programs. While no major new partnerships are announced, the company demonstrates the platform's value, leading to a modest valuation increase to approximately $490M, a 40% upside from the current estimated $350M.

Bear (30%)-40%

Algen faces unforeseen challenges in its preclinical programs or regulatory hurdles, or the AstraZeneca partnership does not progress as anticipated, leading to reduced milestone payments. Increased competition from well-funded incumbents or other AI/CRISPR biotechs erodes market confidence, resulting in a down round or acquisition at a significantly lower valuation of approximately $210M, wiping out a substantial portion of common stock value.

Est. time to liquidity~3.0 years

Preference Stack Risk

low

Investors hold $9M in liquidation preferences, which is 2.57% of the estimated $350M valuation.

Dilution Risk

moderate

As a capital-intensive biotech company with ~14 employees, future funding rounds and expansion of the team will likely lead to further equity dilution.

Secondary Liquidity

none

There is currently no active secondary market or tender offers for Algen Biotechnologies' private shares.

Questions to Ask at the Interview

Strategic questions based on Algen Biotechnologies's data — designed to show you've done your homework.

  • 1

    “How does Algen plan to navigate the competitive landscape with large incumbents like Roche and Novartis increasingly investing in AI/ML for drug discovery, especially given the AstraZeneca partnership?”

  • 2

    “With the significant AstraZeneca deal, how does Algen balance its strategic partnerships with its internal drug development pipeline, and what are the key milestones for revenue growth over the next 2-3 years?”

  • 3

    “Given the 'Later Stage VC' funding and the potential for a large partnership, what is the company's anticipated timeline for a liquidity event, and how does the equity compensation plan account for potential future dilution?”

Community

Valuation Sentiment

Our model estimates -49% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.